# Timberlyne Therapeutics funding rounds and investors

As of 14 Oct 2026, Timberlyne Therapeutics has raised $180M across 1 verified round on record; latest: $180 million Series A led by Abingworth, Bain Capital Life Sciences and 1 other, announced 9 Jan 2025.

Timberlyne Therapeutics develops biopharmaceutical therapies for autoimmune diseases.

Website: https://timberlyne-tx.com  
Page: https://fireround.dev/companies/timberlyne-tx.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-01-09 | Series A | $180 million | Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners | 3H Health, Boyu Capital, Braidwell, Lilly Asia Ventures | [prnewswire.com](https://www.prnewswire.com/news-releases/timberlyne-therapeutics-launches-with-a-180-million-series-a-financing-to-advance-cm313-a-potentially-best-in-class-anti-cd38-monoclonal-antibody-for-diseases-of-high-unmet-medical-needs-302347636.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.